Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCatherine C. Coombs, Michael F. Berger, Aijazuddin Syed et al.|Cell stem cell|2017Cited by 851
Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed <i>FLT3</i> Mutated AMLSelina M. Luger, Mark R. Litzow, Li Chen et al.|Blood|2024Cited by 7